docetaxel
docetaxel
Overview
Docetaxel is a chemotherapeutic agent belonging to the taxane family, primarily used in the treatment of various malignancies, including breast, lung, and prostate cancers. It functions by inhibiting microtubule depolymerization, thereby disrupting the normal mitotic spindle formation during cell division, which ultimately leads to apoptosis in rapidly dividing cancer cells. Its efficacy has made it a cornerstone in cancer therapy, particularly in combination with other treatments such as androgen deprivation therapy (ADT) and immunotherapy.
Focus of Latest Publications
Recent studies have explored the role of docetaxel in various cancer treatment regimens, highlighting its significance in both monotherapy and combination therapies. For instance, a study published in Cancer Biology & Therapy (PMID: 42189063) demonstrated that suppression of long non-coding RNA AC008406.3 sensitizes breast cancer cells to docetaxel by triggering cuproptosis, indicating a novel mechanism to enhance the drug's efficacy in breast cancer.
In the context of lung cancer, a study in Medical Decision Making (PMID: 42037076) utilized a regression discontinuity in time (RDiT) design to compare the effectiveness of second-line pembrolizumab versus docetaxel for advanced non-small-cell lung cancer (aNSCLC), emphasizing the need for real-world evidence in treatment decision-making. Similarly, a comparative analysis in Current Medical Research and Opinion (PMID: 42258330) assessed docetaxel against androgen receptor pathway inhibitors (ARPIs) as first-line treatments for metastatic hormone-sensitive prostate cancer (mHSPC), revealing that both strategies are established but lack direct randomized trials for comparison.
The ARASENS trial (PMID: 41967349) further illustrated the potential of combining docetaxel with darolutamide and ADT, showing a significant reduction in mortality risk among patients with mHSPC. Additionally, a study published in Cancer (PMID: 42175549) evaluated the impact of baseline testosterone levels on the mortality benefit of adding docetaxel to radiation therapy and ADT in nonmetastatic high-risk prostate cancer, underscoring the importance of patient stratification in treatment outcomes.
Docetaxel's role in enhancing immune responses was also highlighted in a study published in Cancer Science (PMID: 41989931), which reported that docetaxel-induced immune activation synergizes with the tumor-targeted CD40 agonist KK2269, showcasing its potential in combination with immunotherapeutic agents. Furthermore, research in International Journal of Cancer (PMID: 41450028) indicated that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 improved pathological responses in locally advanced gastric adenocarcinoma, although robust real-world evidence remains limited.
Overall, these studies reflect a growing interest in optimizing docetaxel's therapeutic applications, exploring its combinations with other agents, and understanding the biological mechanisms that influence its efficacy in various cancer types.